Last reviewed · How we verify
FLOVENT 500mcg
FLOVENT 500mcg is a Inhaled corticosteroid (ICS) Small molecule drug developed by GlaxoSmithKline. It is currently FDA-approved for Maintenance treatment of asthma as prophylactic therapy in patients aged 4 years and older. Also known as: FP 500.
FLOVENT 500mcg is a glucocorticoid receptor agonist, classified as a small molecule in the agonist drug class. It is used to treat conditions such as asthma and chronic obstructive pulmonary disease, as indicated by clinical trials registered on ClinicalTrials.gov.
At a glance
| Generic name | FLOVENT 500mcg |
|---|---|
| Also known as | FP 500 |
| Sponsor | GlaxoSmithKline |
| Drug class | Inhaled corticosteroid (ICS) |
| Target | Glucocorticoid receptor (GR) |
| Modality | Small molecule |
| Therapeutic area | Respiratory |
| Phase | FDA-approved |
Approved indications
- Maintenance treatment of asthma as prophylactic therapy in patients aged 4 years and older
Common side effects
Drug interactions
- ritonavir
- ketoconazole
Key clinical trials
- Sensitivity of Pharmacokinetics to Differences in Aerodynamic Particle Size Distribution (PHASE1)
- Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma
- Mechanism(s) of Airflow Limitation During Exacerbation of Asthma (PHASE4)
- Microbiome Use to Stratify Use of Inhaled Corticosteroids: MUSIC Trial (PHASE4)
- A Bioequivalence Study Between Fluticasone Salmeterol Xinafoate vs. ADVAIR DISKUS® in Healthy Volunteers (PHASE1)
- A Study to Evaluate the 24 Hour Spirometric Effect (FEV1) of Fluticasone Furoate/Vilanterol Inhalation Powder (100mcg Fluticasone Furoate (FF)/25mcg Vilanterol (VI)) Compared With Salmeterol/Fluticasone Propionate Inhalation Powder (50mcg Salmeterol/500mcg Fluticasone Propionate (FP)) (PHASE3)
- SAS115359: A 6-month Study to Assess the Safety and Benefit of Inhaled Fluticasone Propionate/Salmeterol Combination Compared With Inhaled Fluticasone Propionate in the Treatment of Adolescents and Adults (12 Years of Age and Older) With Asthma. (PHASE4)
- Comparative Study on Usability of Inhaler Devices in Adults With Asthma or COPD (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- FLOVENT 500mcg CI brief — competitive landscape report
- FLOVENT 500mcg updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI
Frequently asked questions about FLOVENT 500mcg
What is FLOVENT 500mcg?
What is FLOVENT 500mcg used for?
Who makes FLOVENT 500mcg?
Is FLOVENT 500mcg also known as anything else?
What drug class is FLOVENT 500mcg in?
What development phase is FLOVENT 500mcg in?
What does FLOVENT 500mcg target?
Related
- Drug class: All Inhaled corticosteroid (ICS) drugs
- Target: All drugs targeting Glucocorticoid receptor (GR)
- Manufacturer: GlaxoSmithKline — full pipeline
- Therapeutic area: All drugs in Respiratory
- Indication: Drugs for Maintenance treatment of asthma as prophylactic therapy in patients aged 4 years and older
- Also known as: FP 500
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing